HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methotrexate treatment of advanced head and neck cancers: a dose response evaluation.

Abstract
Fifty-eight patients with advanced squamous cell cancer of the head and neck have been randomized on a study comparing three different weekly methotrexate (MTX) dose levels followed at 24 hours by standardized folinic acid rescue. Eighteen patients received MTX 5 g/m2, 24 patients received 500 mg/m2, and 16 patients received 50 mg/m2. The initial response rate according to treatment were 50%, 21% and 31%, respectively. Six patients crossed from low- to medium-dose MTX after failing to respond (four) or relapsing, and one in each group had a tumor response. Eleven patients crossed over from initial medium-dose to high-dose MTX after failing to respond (ten) or relapsing, and one in each group had a tumor response. The median time to maximum response was 3.5 weeks. There were only two complete responders, and one is disease free more than 19 months after starting treatment and more than 15 months after stopping treatment. The high-dose MTX treatment was significantly more toxic than lower doses, and there were four drug-related deaths (three in the high-dose group). The preliminary results of this study support the notion of a dose-response relationship to MTX in advanced squamous cell cancer of the head and neck.
AuthorsR L Woods, R M Fox, M H Tattersall
JournalCancer treatment reports (Cancer Treat Rep) Vol. 65 Suppl 1 Pg. 155-9 ( 1981) ISSN: 0361-5960 [Print] United States
PMID7034929 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Leucovorin
  • Methotrexate
Topics
  • Adolescent
  • Adult
  • Aged
  • Carcinoma, Squamous Cell (drug therapy, mortality)
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Head and Neck Neoplasms (drug therapy, mortality)
  • Humans
  • Leucovorin (administration & dosage)
  • Male
  • Methotrexate (administration & dosage, adverse effects)
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: